Navigation Links
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
Date:5/16/2013

ain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

AbbVie forward-looking statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicabl
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
2. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
3. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
4. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
5. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie to Host First-Quarter Earnings Conference Call
8. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
9. AbbVie to Present at Barclays Global Health Care Conference
10. AbbVie Issues Inaugural Full-Year Outlook for 2013
11. AbbVie Named to S&P 500 Dividend Aristocrat Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... Beverly Hills, CA (PRWEB) July 31, 2014 ... president George W. Bush recently underwent partial knee replacement surgery ... right knee less than two months earlier. The story also ... between the procedures and hopes to be back on the ... replacement surgery highlights the benefits of partial knee replacement. ...
(Date:7/31/2014)... 2014 Recognizing that today’s medical students ... Healthcare Conference announced today its student discount program. ... medicine or a healthcare-related field, as well as medical ... discounts for the conference, scheduled for September 17-20, 2014 ... Resort. , “As a future Registered Dietitian, ...
(Date:7/31/2014)... ProtonPACS, a division of Radsource, has signed ... Health Association (NRHA), company officials announced today. The partnership ... of rural health providers nationwide. , “We are proud ... Dr. Mark Awh, President of Radsource. “While we are ... are also looking forward to learning from all of ...
(Date:7/31/2014)... The shale gas development that has vaulted ... U.S. natural gas production has raised concerns that local ... similar to previous resource extraction experiences in Pennsylvania’s history. ... & Jefferson College’s (W&J) Center for Energy Policy & ... that the gas boom in Pennsylvania is still underway, ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
Breaking Medicine News(10 mins):Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Women in military less likely to drink than civilian women 2
... James "Buster" Douglas, former World Heavyweight Boxing Champion, ... brand new inspirational diabetic diet cookbook. "Take a ... Bar-B-Q Knockout Diabetes Diet," available now on Amazon.com ... to order for Mother,s Day, Sunday, May 10, ...
... Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, ... on May 7, 2009 (the "Expiry Time") 31,411,927 Restricted Voting ... deposited to JLL,s offer to acquire, at a price of ... and outstanding Restricted Voting Shares of Patheon (the "Offer"). As ...
... Universal Capital Management, Inc. (OTC Bulletin Board: UCMT), ... management and strategic growth resources to emerging growth ... ("Vystar") and Alatech Healthcare, LLC announced 510(k) clearance ... to market and sell Alatech,s Envy(TM) condom manufactured ...
... less cardiovascular disease than those who smoke, according ... and women in Norway. Smoking, say the investigators, ... from various causes. , The results, presented in ... studies have indicated, but, says investigator Professor Haakon ...
... preventive measures identified by the European Heart Health ... of EuroPRevent 2009, the congress of the European ... takes place in Stockholm, Sweden, on 6-9 May. ... is shown to improve markers of heart disease ...
... Netherlands: New research that uses an innovative approach to study, ... exercise habits to the development of the obesity epidemic has ... since the 1970s was virtually all due to increased energy ... has been caused by excess calorie intake and how much ...
Cached Medicine News:Health News:President Obama's New Knockout Mother's Day Message from Champ 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 2Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 4Health News:30-year follow-up study: 'Tremendous' impact of smoking on mortality and cardiovascular disease 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 3Health News:Increased food intake alone explains the increase in body weight in the United States 2Health News:Increased food intake alone explains the increase in body weight in the United States 3
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: